NUCANA PLC-ADR (NCNA)       1.04  +0.02 (+1.96%)

1.04  +0.02 (+1.96%)

US67022C1062 - ADR

NUCANA PLC-ADR1.04

NASDAQ:NCNA (10/4/2022, 10:29:33 AM)+0.02 (+1.96%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-17 2022-08-17/amc Earnings (Next) 11-16 2022-11-16
Ins Owners N/A Inst Owners 26.58%
Market Cap 54.28M Shares 52.20M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 85.45
IPO 09-28 2017-09-28

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

NCNA Daily chart

Company Profile

NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes Acelari, NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The firm is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. The Company’s subsidiaries include NuCana, Inc. and NuCana BioMed Trustee Company Limited.

Company Info

NUCANA PLC-ADR

Lochside House, 3 Lochside Way

Edinburgh EH12 9DT

P: 4401313571111.0

CEO: Hugh Griffith

Employees: 31

Website: http://www.nucana.com/

NCNA News

News Image22 days ago - NuCana plcNuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

NUC-7738 Demonstrates Encouraging Anti-Tumor Activity and a Favorable Safety Profile Across a Variety of Solid Tumors NUC-7738 Monotherapy and Combination...

News Imagea month ago - NuCana plcNuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

EDINBURGH, United Kingdom, Sept. 06, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two presentations at the European Society for Medical...

News Imagea month ago - NuCana plcNuCana to Participate in Citi's 17th Annual BioPharma Conference

EDINBURGH, United Kingdom, Aug. 31, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that management will host one-on-one meetings at...

News Image2 months ago - NuCana plcNuCana Reports Second Quarter 2022 Financial Results and Provides Business Update

Multiple Data Readouts on Track for the Second Half of 2022 and the First Half of 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH,...

NCNA Twits

Here you can normally see the latest stock twits on NCNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example